Hematopoietic stem cell therapy for type 1 diabetes: Induction of tolerance and islet cell neogenesis

Richard K. Burt, Yu Oyama, Ann Traynor, Norma S Kenyon

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Diabetes is a chronic disease with significant morbidity and mortality. Pancreas or islet cell transplantation is limited by a shortage of donors and chronic immune suppression to prevent allograft rejection. Consequently, interest exists in islet cell neogenesis from embryonic or mesenchymal stem cell as a possible cure for diabetes. However, unless tolerance to islet cells is re-established, diabetes treated by islet cell transplantation would remain a chronic disease secondary to immune suppression related morbidity. If islet cell tolerance could be re-induced, a major clinical hurdle to curing diabetes by islet cell neogenesis may be overcome. Recent studies suggest that adult hematopoietic stem cells (HSC) can reintroduce tolerance to auto-antigens. It is possible that HSC may also be able to switch lineage and, therefore, be a convenient source of stem cells for both inducing tolerance and islet cell regeneration.

Original languageEnglish
Pages (from-to)133-138
Number of pages6
JournalAutoimmunity Reviews
Volume1
Issue number3
DOIs
StatePublished - May 1 2002

Fingerprint

Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Type 1 Diabetes Mellitus
Islets of Langerhans
Islets of Langerhans Transplantation
Cell Transplantation
Chronic Disease
Morbidity
Adult Stem Cells
Embryonic Stem Cells
Mesenchymal Stromal Cells
Allografts
Regeneration
Pancreas
Stem Cells
Antigens
Mortality

Keywords

  • Islet cell neogenesis
  • Stem cell therapy
  • Type 1 diabetes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Hematopoietic stem cell therapy for type 1 diabetes : Induction of tolerance and islet cell neogenesis. / Burt, Richard K.; Oyama, Yu; Traynor, Ann; Kenyon, Norma S.

In: Autoimmunity Reviews, Vol. 1, No. 3, 01.05.2002, p. 133-138.

Research output: Contribution to journalArticle

@article{d9e06ab5e49c4f9c977f854fa9d194b8,
title = "Hematopoietic stem cell therapy for type 1 diabetes: Induction of tolerance and islet cell neogenesis",
abstract = "Diabetes is a chronic disease with significant morbidity and mortality. Pancreas or islet cell transplantation is limited by a shortage of donors and chronic immune suppression to prevent allograft rejection. Consequently, interest exists in islet cell neogenesis from embryonic or mesenchymal stem cell as a possible cure for diabetes. However, unless tolerance to islet cells is re-established, diabetes treated by islet cell transplantation would remain a chronic disease secondary to immune suppression related morbidity. If islet cell tolerance could be re-induced, a major clinical hurdle to curing diabetes by islet cell neogenesis may be overcome. Recent studies suggest that adult hematopoietic stem cells (HSC) can reintroduce tolerance to auto-antigens. It is possible that HSC may also be able to switch lineage and, therefore, be a convenient source of stem cells for both inducing tolerance and islet cell regeneration.",
keywords = "Islet cell neogenesis, Stem cell therapy, Type 1 diabetes",
author = "Burt, {Richard K.} and Yu Oyama and Ann Traynor and Kenyon, {Norma S}",
year = "2002",
month = "5",
day = "1",
doi = "10.1016/S1568-9972(02)00033-2",
language = "English",
volume = "1",
pages = "133--138",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Hematopoietic stem cell therapy for type 1 diabetes

T2 - Induction of tolerance and islet cell neogenesis

AU - Burt, Richard K.

AU - Oyama, Yu

AU - Traynor, Ann

AU - Kenyon, Norma S

PY - 2002/5/1

Y1 - 2002/5/1

N2 - Diabetes is a chronic disease with significant morbidity and mortality. Pancreas or islet cell transplantation is limited by a shortage of donors and chronic immune suppression to prevent allograft rejection. Consequently, interest exists in islet cell neogenesis from embryonic or mesenchymal stem cell as a possible cure for diabetes. However, unless tolerance to islet cells is re-established, diabetes treated by islet cell transplantation would remain a chronic disease secondary to immune suppression related morbidity. If islet cell tolerance could be re-induced, a major clinical hurdle to curing diabetes by islet cell neogenesis may be overcome. Recent studies suggest that adult hematopoietic stem cells (HSC) can reintroduce tolerance to auto-antigens. It is possible that HSC may also be able to switch lineage and, therefore, be a convenient source of stem cells for both inducing tolerance and islet cell regeneration.

AB - Diabetes is a chronic disease with significant morbidity and mortality. Pancreas or islet cell transplantation is limited by a shortage of donors and chronic immune suppression to prevent allograft rejection. Consequently, interest exists in islet cell neogenesis from embryonic or mesenchymal stem cell as a possible cure for diabetes. However, unless tolerance to islet cells is re-established, diabetes treated by islet cell transplantation would remain a chronic disease secondary to immune suppression related morbidity. If islet cell tolerance could be re-induced, a major clinical hurdle to curing diabetes by islet cell neogenesis may be overcome. Recent studies suggest that adult hematopoietic stem cells (HSC) can reintroduce tolerance to auto-antigens. It is possible that HSC may also be able to switch lineage and, therefore, be a convenient source of stem cells for both inducing tolerance and islet cell regeneration.

KW - Islet cell neogenesis

KW - Stem cell therapy

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=1542509670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542509670&partnerID=8YFLogxK

U2 - 10.1016/S1568-9972(02)00033-2

DO - 10.1016/S1568-9972(02)00033-2

M3 - Article

C2 - 12849006

AN - SCOPUS:1542509670

VL - 1

SP - 133

EP - 138

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 3

ER -